Validation of Reduced S-gene Target Performance and Failure for Rapid Surveillance of SARS-CoV-2 Variants

Cyndi Clark, Joshua Schrecker, Matthew Hardison, Michael S. Taitel
doi: https://doi.org/10.1101/2022.04.18.22273989

Article Information

doi 
https://doi.org/10.1101/2022.04.18.22273989
History 
  • May 6, 2022.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Cyndi Clark, PhD1,3,
  2. Joshua Schrecker, PharmD1,3,
  3. Matthew Hardison, PhD1 and
  4. Michael S. Taitel, PhD2,*
  1. 1Aegis Sciences Corporation, Nashville, TN
  2. 2Walgreens, Deerfield, IL
  1. ↵*Corresponding Author: Michael S. Taitel, PhD Michael.taitel{at}walgreens.com

  1. ↵3 These authors contributed equally to this manuscript.

Back to top
Posted May 06, 2022.
Download PDF
Data/Code
Email
Validation of Reduced S-gene Target Performance and Failure for Rapid Surveillance of SARS-CoV-2 Variants
Cyndi Clark, Joshua Schrecker, Matthew Hardison, Michael S. Taitel
medRxiv 2022.04.18.22273989; doi: https://doi.org/10.1101/2022.04.18.22273989
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area